Major diabetes drug Victoza has received a strong boost on the way to approval. The European Medicines Agency gave Novo Nordisk the good news, following a blow from American experts who remain unsure about the safety of the drug .
Following the news, shares in the Danish company climbed 5 per cent in US trading. The diabetes drug company intend to launch the drug this summer across a number of European markets.
The Food and Drug Administration voted 6-6 regarding thyroid tumours found in rats and mice that the drug was tested on. Fears are running high that the FDA will possibly block the drug or at the least delay its launch.
The drug is part of a new class of injectable drugs for people with diabetes, the core function of which is to stimulate insulin release if glucose levels become too high.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…